Article in Infectious diseases of poverty, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Shan LvNational Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research); Key Laboratory On Parasite and Vector Biology, National Health Commission; WHO Collaborating Centre for Tropical Diseases; National Center for International Research on Tropical Diseases, Ministry of Science and Technology, Shanghai, PR China. lvshan@nipd.chinacdc.cn.ORCID http://orcid.org/0000-0003-2086-807X
Li-Gang ZhouNational Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research); Key Laboratory On Parasite and Vector Biology, National Health Commission; WHO Collaborating Centre for Tropical Diseases; National Center for International Research on Tropical Diseases, Ministry of Science and Technology, Shanghai, PR China.
Jing XuNational Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research); Key Laboratory On Parasite and Vector Biology, National Health Commission; WHO Collaborating Centre for Tropical Diseases; National Center for International Research on Tropical Diseases, Ministry of Science and Technology, Shanghai, PR China.
Shi-Zhu LiNational Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research); Key Laboratory On Parasite and Vector Biology, National Health Commission; WHO Collaborating Centre for Tropical Diseases; National Center for International Research on Tropical Diseases, Ministry of Science and Technology, Shanghai, PR China.
Robert BergquistGeospatial Health, Brastad, Sweden.
Jürg UtzingerSwiss Tropical and Public Health Institute, Allschwil, Switzerland.
Xiao-Nong ZhouNational Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research); Key Laboratory On Parasite and Vector Biology, National Health Commission; WHO Collaborating Centre for Tropical Diseases; National Center for International Research on Tropical Diseases, Ministry of Science and Technology, Shanghai, PR China.
Funding
National Key Research and Development Program of China No. 2024YFC2310902
6 · The paper itself
Abstract
Schistosomiasis was first reported in the People's Republic of China (P.R. China) 120 years ago. The national programme of schistosomiasis control started in mid-1950s. The transmission interruption was achieved by 2023. Here we summarize the experience as the five core parts of a running chariot. While the specific historical context of P.R. China's way of schistosomiasis control may be difficult to replicate, the experiences gained underscore several critical principles that might be applicable elsewhere.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
From endemic shadows to the light of dawn: the 120-year journey of China's anti-schistosomiasis chariot. · full record | OpenQuestion